A multinational clinical study on Regenerative Peripheral Nerve Interface surgery for symptomatic neuromas and related pain in lower limb amputees is recruiting, signaling a regulatory focus on regenerative nerve interfaces. The sponsor is Saglik Bilimleri Universitesi.
What is Regenerative Peripheral Nerve Interface and who may be affected?
The trial investigates Regenerative Peripheral Nerve Interface surgery as an intervention for symptomatic neuroma and related pain in people who have undergone lower limb amputation. The conditions addressed in the study include symptomatic neuroma, phantom limb pain after amputation, residual limb pain and neuropathic pain affecting the lower extremity. The approach targets a population that experiences nerve related discomfort after limb loss and seeks to determine if the procedure can alleviate distressing symptoms that hinder rehabilitation and daily function.
What are the trial details and current status?
The study is sponsored by Saglik Bilimleri Universitesi and is currently Recruiting. The public record notes the trial identifier NCT07420192 and indicates a focus on a regenerative nerve interface procedure in a device context. Specific endpoints, sample size, and detailed protocol elements are not disclosed in the provided source text, which is typical for early stage listings. Clinicians and institutions may review the public information for preliminarily described objectives and inclusion criteria.
Clinical Trials entry: https://clinicaltrials.gov/study/NCT07420192?term=medical+device
What are the regulatory implications for device evaluation?
Under the regulatory framework applicable to regenerative devices, authorities require evidence on intended use, performance and safety. Trials such as this contribute to the data pool used to assess potential benefits and risks of Regenerative Peripheral Nerve Interface technology for symptomatic neuroma and related neuropathic pain in lower extremity amputation care. The sponsorship by a university program and the trial’s status signal active data collection that may inform future regulatory submissions, labeling considerations and risk management planning in accordance with MDR Annex XIV style expectations. It is important to distinguish between the trial record and a final regulatory decision, as conclusions will depend on complete results and peer review.
What comes next for clinicians and regulators?
If subsequent findings indicate acceptable safety and potential clinical benefit, the accumulated evidence could support future device submissions or expanded indications. Regulators would weigh this information alongside existing guidance and clinical practice standards to determine appropriate risk management measures, post market surveillance obligations and labeling recommendations. Clinicians may anticipate evolving guidelines for using regenerative nerve interface strategies to manage pain related to nerve pathology after limb loss, which could influence patient care pathways in rehabilitation and surgery settings.
Frequently asked questions
- 1. What is the focus of the trial? It evaluates Regenerative Peripheral Nerve Interface surgery for symptomatic neuroma and related pain in lower limb amputees. The study aims to clarify whether the procedure can relieve pain and improve function in this population.
- 2. Who sponsors the trial? Saglik Bilimleri Universitesi is listed as the sponsor, indicating academic oversight and collaboration with clinical sites.
- 3. How can I learn more? See the ClinicalTrials.gov entry NCT07420192, which provides the official trial details and status updates as they become available.
Conclusion
The ongoing recruitment for the Regenerative Peripheral Nerve Interface study in lower limb amputees reflects a measured regulatory and clinical interest in regenerative nerve technologies. Clinicians and regulators should monitor the evolving evidence from this trial as it becomes available, with attention to safety signals, outcome measures and the potential for future device submissions that align with MDR expectations for performance and risk management.
Disclaimer: This article is intended for professional audiences. It is not legal advice or regulatory guidance. It reflects information from the trial record and related regulatory context as presented in the source text.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07420192?term=medical+device